The molecular cloning and the expression of the Salmonella typhi (ST) 36 kDal porin in Escherichia coli, the sequence analysis of its gene, the preparation of monoclonal antibodies against this antigen, and immunoblots and radioimmunoprecipitations assays of labeled ST whole cells have indicated that this porin protein is immunogenic and exposed on the surface of ST. The same studies indicate that some of the exposed epitopes correspond to regions of the porin that are available among different species of Enterobacteria and that the immune response to them could be used to detect infection by ST. Thus, purified 36 kDal ST porin will be used to develop assays to detect antibodies against the porin, in the sera of typhoid fever patients, using an ELISA assay. The specificity and sensitivity of this antibody detection assay will be determined, compared to present diagnostic tests such as the Widal reaction, validated using a limited sample of well characterized sera from patients, and sera from patients with other bacteremic diseases and normal sera as controls. The need for this assay is clear; there is a recrudescence of typhoid fever in developing countries, and the lack of adequate methodology to make an early diagnosis of the disease. Awardee's statement of the potential commercial applications of the research: The assay developed can be commercialized in countries that are involved in efforts to control typhoid fever. It can also be sold to institutions dealing with travelers to developing countries, to the Health Services of Armed Forces, and other institutions with personnel operating in areas where typhoid fever is endemic. The total market for this type of diagnostic assay should be at least 15,000,000 units per year.National Institute of Allergy and Infectious Diseases (NIAID)
